{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:37:46Z","timestamp":1791074266918,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.pupt.2011.09.003","type":"journal-article","created":{"date-parts":[[2011,9,25]],"date-time":"2011-09-25T20:26:15Z","timestamp":1316982375000},"page":"638-646","source":"Crossref","is-referenced-by-count":24,"title":["YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice"],"prefix":"10.1016","volume":"24","author":[{"given":"Jin Won","family":"Huh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Song","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2011.09.003_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.200801-029UP","article-title":"Update in pulmonary arterial hypertension 2007","volume":"177","author":"Humbert","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ncpcardio0890","article-title":"Pulmonary arterial hypertension: current therapeutic strategies","volume":"4","author":"Puri","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2010.11.020","article-title":"Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective","volume":"57","author":"Gomberg-Maitland","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pupt.2011.09.003_bib4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","article-title":"Pulmonary arterial hypertension","volume":"114","author":"McLaughlin","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2011.09.003_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.pathol.2.010506.092033","article-title":"Pathobiology of pulmonary hypertension","volume":"2","author":"Rabinovitch","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.pupt.2011.09.003_bib6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/rccm.201009-1393PP","article-title":"HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease","volume":"183","author":"Shimoda","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pupt.2011.09.003_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1172\/JCI5912","article-title":"Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha","volume":"103","author":"Yu","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pupt.2011.09.003_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pupt.2011.09.003_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bjp.0704876","article-title":"Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs","volume":"137","author":"Keeble","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.1994.tb12039.x","article-title":"Soluble guanylyl cyclase and platelet function","volume":"714","author":"Buechler","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl E","key":"10.1016\/j.pupt.2011.09.003_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/12.suppl_E.2","article-title":"Endothelium-derived nitric oxide: the endogenous nitrovasodilator in the human cardiovascular system","volume":"12","author":"L\u00fcscher","year":"1991","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2011.09.003_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pupt.2011.09.003_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1124\/mol.53.1.123","article-title":"Mechanism of YC-1-induced activation of soluble guanylyl cyclase","volume":"53","author":"Friebe","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1006\/bbrc.2002.6552","article-title":"YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function","volume":"291","author":"Tulis","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pupt.2011.09.003_bib17","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/sj.onc.1210169","article-title":"YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt\/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia","volume":"26","author":"Sun","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pupt.2011.09.003_bib18","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1535-7163.MCT-08-0074","article-title":"A\u00a0novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pupt.2011.09.003_bib19","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pupt.2011.09.003_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1164\/ajrccm.163.5.2003144","article-title":"Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia","volume":"163","author":"van Suylen","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1164\/rccm.200501-041OC","article-title":"Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs","volume":"172","author":"Lee","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/01.RES.0000188211.83193.1a","article-title":"Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1\/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice","volume":"97","author":"Yu","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.pupt.2011.09.003_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4161\/cc.5.8.2687","article-title":"Check, double check: the G2 barrier to cancer","volume":"5","author":"Foijer","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pupt.2011.09.003_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1165\/rcmb.2003-0397OC","article-title":"p42\/44 Mitogen-activated protein kinase regulated by p53 and nitric oxide in human pulmonary arterial smooth muscle cells","volume":"31","author":"Mizuno","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pupt.2011.09.003_bib25","doi-asserted-by":"crossref","first-page":"L753","DOI":"10.1152\/ajplung.00286.2010","article-title":"p53 gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice","volume":"300","author":"Mizuno","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pupt.2011.09.003_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.109.891077","article-title":"Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation","volume":"121","author":"Zuckerbraun","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2011.09.003_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bcp.2007.08.011","article-title":"Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226","volume":"75","author":"Chen","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib28","first-page":"R1260","article-title":"Normobaric hypoxia stimulates endothelin-1 gene expression in the rat","volume":"263","author":"Elton","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pupt.2011.09.003_bib29","first-page":"L690","article-title":"ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat","volume":"269","author":"DiCarlo","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pupt.2011.09.003_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/07853890310004093","article-title":"Signaling through NO and cGMP-dependent protein kinases","volume":"35","author":"Schlossmann","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.pupt.2011.09.003_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI114477","article-title":"Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide","volume":"85","author":"Boulanger","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pupt.2011.09.003_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI116604","article-title":"Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia","volume":"92","author":"Kourembanas","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pupt.2011.09.003_bib33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1124\/mol.54.6.962","article-title":"YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets","volume":"54","author":"Friebe","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.59.2.220","article-title":"Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells","volume":"59","author":"Schmidt","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjp.0702495","article-title":"Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity","volume":"127","author":"Galle","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"46","key":"10.1016\/j.pupt.2011.09.003_bib36","doi-asserted-by":"crossref","first-page":"44085","DOI":"10.1074\/jbc.M205934200","article-title":"Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension","volume":"277","author":"Murata","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pupt.2011.09.003_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0026-895X(24)05639-6","article-title":"YC-1-induced cyclooxygenase-2 expression is mediated by cGMP-dependent activations of Ras, phosphoinositide-3-OH-kinase, Akt, and nuclear factor-kappaB in human pulmonary epithelial cells","volume":"66","author":"Chang","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/21224","article-title":"Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation","volume":"399","author":"Dimmeler","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pupt.2011.09.003_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0006-2952(01)00564-0","article-title":"Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells","volume":"61","author":"Chun","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib40","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/0008-5472.CAN-05-4460","article-title":"YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases","volume":"66","author":"Yeo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.pupt.2011.09.003_bib41","first-page":"255","article-title":"A\u00a0domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent","volume":"29","author":"Kim","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pupt.2011.09.003_bib42","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.bbrc.2006.08.015","article-title":"Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2)","volume":"348","author":"Lau","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pupt.2011.09.003_bib43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.exer.2009.06.013","article-title":"Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis","volume":"89","author":"DeNiro","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.pupt.2011.09.003_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/mol.109.061366","article-title":"Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy","volume":"77","author":"DeNiro","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pupt.2011.09.003_bib45","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1172\/JCI33452","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"118","author":"Rabinovitch","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pupt.2011.09.003_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bjp.0703320","article-title":"Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats","volume":"130","author":"Rothermund","year":"2000","journal-title":"Br J Pharmacol"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:00:51Z","timestamp":1741741251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553911001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1094553911001453"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2011.09.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}